Can No­vo Nordisk's block­buster weight loss drug and oth­er GLP-1s al­so work in NASH? The an­swer is com­pli­cat­ed

Back in 2020, be­fore semaglu­tide be­came a house­hold name — be­fore it was even ap­proved to treat obe­si­ty — No­vo Nordisk qui­et­ly notched a break­through ther­a­py des­ig­na­tion in a hot in­di­ca­tion: non­al­co­holic steato­hep­ati­tis, or NASH.

Three years lat­er, the GLP-1 re­cep­tor ag­o­nist has emerged as one of the “most rec­og­nized and an­tic­i­pat­ed” new treat­ments for a dis­ease that’s been dubbed a silent killer and de­feat­ed mul­ti­ple ex­per­i­men­tal drugs. No­vo is still re­cruit­ing NASH pa­tients with fi­bro­sis in a 1200-pa­tient Phase II­Ia study, with da­ta not ex­pect­ed un­til 2028.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.